Connor Clark & Lunn Investment Management Ltd. Buys 12,604 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR)

Connor Clark & Lunn Investment Management Ltd. increased its stake in OraSure Technologies, Inc. (NASDAQ:OSUR) by 78.2% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 28,731 shares of the medical instruments supplier’s stock after buying an additional 12,604 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in OraSure Technologies were worth $123,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Millennium Management LLC grew its stake in shares of OraSure Technologies by 727.5% in the second quarter. Millennium Management LLC now owns 2,021,126 shares of the medical instruments supplier’s stock worth $8,610,000 after acquiring an additional 1,776,867 shares during the last quarter. Acadian Asset Management LLC grew its position in OraSure Technologies by 38.1% during the 2nd quarter. Acadian Asset Management LLC now owns 2,195,582 shares of the medical instruments supplier’s stock valued at $9,349,000 after purchasing an additional 605,324 shares during the last quarter. American Century Companies Inc. increased its stake in OraSure Technologies by 30.1% during the 2nd quarter. American Century Companies Inc. now owns 1,809,897 shares of the medical instruments supplier’s stock valued at $7,710,000 after purchasing an additional 418,603 shares in the last quarter. Renaissance Technologies LLC raised its holdings in OraSure Technologies by 20.6% in the second quarter. Renaissance Technologies LLC now owns 2,288,443 shares of the medical instruments supplier’s stock worth $9,749,000 after buying an additional 391,100 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA bought a new position in shares of OraSure Technologies in the second quarter worth approximately $1,602,000. Institutional investors own 93.50% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on OSUR shares. Evercore ISI raised their price target on shares of OraSure Technologies from $4.50 to $5.00 and gave the company an “in-line” rating in a research report on Wednesday, August 7th. StockNews.com raised OraSure Technologies from a “hold” rating to a “buy” rating in a report on Friday, October 4th.

OraSure Technologies Stock Down 1.0 %

Shares of OSUR stock opened at $3.80 on Monday. The firm has a market capitalization of $283.46 million, a PE ratio of 25.33 and a beta of 0.05. The company has a 50 day moving average price of $4.09 and a 200-day moving average price of $4.29. OraSure Technologies, Inc. has a 52 week low of $3.72 and a 52 week high of $8.45.

OraSure Technologies (NASDAQ:OSUR) last announced its earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The business had revenue of $39.92 million during the quarter, compared to analyst estimates of $38.97 million. OraSure Technologies had a net margin of 5.07% and a return on equity of 3.55%. The company’s quarterly revenue was down 55.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.27 EPS. Analysts anticipate that OraSure Technologies, Inc. will post -0.09 earnings per share for the current year.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.